MovDisordV3, PascalFrancis, Checkpoint, bibRecord, 001768

Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism

Identifieur interne : 001768 ( PascalFrancis/Checkpoint ); précédent : 001767; suivant : 001769

Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism

Auteurs : Laura Bonanni [Italie] ; Astrid Thomas [Italie] ; Sara Varanese [Italie] ; Vincenzo Scorrano [Italie] ; Marco Onofrj [Italie]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:08-0069702

Descripteurs français

Pascal (Inist)
- Pathologie du système nerveux, Dystonie, Parkinsonisme, Maladie de Parkinson, Bontoxilysin, Traitement.

English descriptors

KwdEn :
- Bontoxilysin, Dystonia, Nervous system diseases, Parkinson disease, Parkinsonism, Treatment.

Abstract

Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross-over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched-over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow-up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross-over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism.

Affiliations:

Italie

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001473
to stream PascalFrancis, to step Curation: 001846

Links to Exploration step

Pascal:08-0069702

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism</title>
<author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0069702</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0069702 INIST</idno>
<idno type="RBID">Pascal:08-0069702</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001473</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001846</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001768</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism</title>
<author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Dystonia</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du   système nerveux</term>
<term>Dystonie</term>
<term>Parkinsonisme</term>
<term>Maladie de Parkinson</term>
<term>Bontoxilysin</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross-over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched-over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow-up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross-over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>14</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BONANNI (Laura)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>THOMAS (Astrid)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VARANESE (Sara)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SCORRANO (Vincenzo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ONOFRJ (Marco)</s1>
</fA11>
<fA14 i1="01"><s1>Neurophysiopathology, University G. D'Annunzio of Chieti-Pescara</s1>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti</s1>
<s2>Pescara</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>2097-2103</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000174393170130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0069702</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross-over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched-over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow-up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross-over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17H</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Distonía</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>44</s5>
</fC07>
<fN21><s1>035</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
</noRegion>
<name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
<name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001768 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001768 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:08-0069702
   |texte=   Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism

Botulinum Toxin Treatment of Lateral Axial Dystonia in Parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri